Novartis Ag (NVS) Non-Current Deferred Tax Liability (2009 - 2026)

Novartis Ag has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $5.3 billion for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability rose 128.01% year-over-year to $5.3 billion; the TTM figure through Jun 2026 stood at $5.3 billion (up 128.01% YoY), while the FY2025 annual figure was $3.4 billion, up 40.43% from the prior year.
• Non-Current Deferred Tax Liability came in at $5.3 billion for Q2 2026 at Novartis Ag, up from $5.1 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $5.3 billion in Q2 2026 to a low of -$276.0 million in Q1 2022.
• Average Non-Current Deferred Tax Liability over 5 years is $2.7 billion, with a median of $2.5 billion recorded in 2023.
• Year-over-year, Non-Current Deferred Tax Liability sank 790.32% in 2022 and soared 1088.04% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $2.7 billion in 2022, then slipped by 16.31% to $2.2 billion in 2023, then advanced by 7.61% to $2.4 billion in 2024, then surged by 40.43% to $3.4 billion in 2025, then jumped by 55.78% to $5.3 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $5.3 billion in Q2 2026, $5.1 billion in Q1 2026, and $3.4 billion in Q4 2025.